GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » Owner Earnings per Share (TTM)
中文

Endo International (Endo International) Owner Earnings per Share (TTM) : -2.94 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Endo International Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Endo International's Owner Earnings per Share (TTM) ended in Dec. 2023 was $-2.94. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Endo International's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Endo International was 251.69. The lowest was 0.01. And the median was 5.51.


ENDPQ's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Endo International's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-10.38. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.41. It's PE Ratio ratio for today is At Loss.

Endo International's EPS without NRI for the three months ended in Dec. 2023 was $-2.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.13. It's PE Ratio without NRI ratio for today is At Loss.


Endo International Owner Earnings per Share (TTM) Historical Data

The historical data trend for Endo International's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International Owner Earnings per Share (TTM) Chart

Endo International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.87 -0.12 -1.19 -9.57 -2.94

Endo International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.57 -10.09 -1.15 0.06 -2.94

Competitive Comparison of Endo International's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Endo International's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endo International's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo International's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Endo International's Price-to-Owner-Earnings falls into.



Endo International Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Endo International's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -2,450
Depreciation, Depletion and Amortization 306
Change In Deferred Tax 5
5Y Average of Maintenance Capital Expenditure 217
Change In Working Capital 1,665
Shares Outstanding (Diluted Average) 235

1. Start with "Net Income" from income statement. Endo International's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-2,450 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Endo International's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $306 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Endo International's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $5 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $217 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Endo International's 5-Year Average Maintenance Capital Expenditure = $217 Mil

5. "Change In Working Capital" is from cashflow statement. Endo International's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $1,665 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Endo International's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 235.219 Mil.

Endo International's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -2449.807 +306.448+4.702
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-217.11136333015+1664.786)/235.219
=-2.94

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.0006/-2.94
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Endo International Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Endo International's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo International (Endo International) Business Description

Traded in Other Exchanges
Address
Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.
Executives
James Patrick Tursi officer: Executive VP, Global R&D 106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti officer: VP, Controller and CAO C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague director
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol officer: EVP, Head of Global R&D C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith director 3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley officer: EVP, Chief Financial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio director 19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle officer: SVP, Interim Controller C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel director LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico officer: EVP & Chief Commercial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella officer: EVP, Intl Pharmaceuticals C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol officer: VP, Controller & CAO 927 GRANDVIEW DRIVE, EXTON PA 19341

Endo International (Endo International) Headlines